多西他赛和奥沙利铂联合替吉奥三联治疗晚期胃癌的效果观察  

Effects of Docetaxel,Oxaliplatin combined with Tegafur triple therapy on advanced gastric cancer

作　　者：邓有晓 李强[1] 董建华[1] 田昌平 余昆[1] DENG Youxiao;LI Qiang;DONG Jianhua;TIAN Changping;YU Kun(Department of Colorectal Surgery of the Third Affiliated Hospital of Kunming Medical University,Kunming 650118 Yunnan,China)

机构地区：[1]昆明医科大学第三附属医院结直肠外科

出　　处：《中国民康医学》2019年第17期11-12,20,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:观察多西他赛和奥沙利铂联合替吉奥三联治疗晚期胃癌的效果。方法:回顾性分析2015年10月至2016年10月的70例行化疗的晚期胃癌患者的临床资料,根据化疗方案不同将其分为对照组32例与观察组38例。对照组采用奥沙利铂和替吉奥治疗,观察组在对照组治疗方案上加用多西他赛治疗,比较两组临床疗效、生命质量、不良反应发生率及生存率。结果:观察组治疗总有效率为68.4%,显著高于对照组的43.8%,差异有统计学意义(P<0.05);治疗前,两组生命质量评分比较,差异无统计学意义(P>0.05),治疗后,观察组生命质量评分(72.24±6.08)分,显著高于对照组(68.19±5.66)分,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05);观察组1年生存率及2年生存率均显著高于对照组,差异有统计学意义(P<0.05)。结论:应用多西他赛和奥沙利铂联合替吉奥治疗晚期胃癌患者的效果优于奥沙利铂联合替吉奥治疗效果,可有效提高患者生命质量,延长患者生存时间。Objective:To observe effects of Docetaxel,Oxaliplatin combined with Tegafur triple therapy in treatment of advanced gastric cancer.Methods:The clinical data of 70 patients with advanced gastric cancer who underwent chemotherapy were retrospectively analyzed.According to different chemotherapy regimens,they were divided into control group(n=32) and observation group(n=32).The control group was treated with Oxaliplatin and Tegafur,while the observation group was treated with Docetaxel based on that of the control group.The clinical efficacy,quality of life,adverse reaction rate and survival rate were compared between the two groups.Results:The total effective rate of the observation group was 68.4%,which was significantly higher than that of the control group(43.8%),and the difference was statistically significant(P<0.05).Before the treatment,there was no statistical difference in the quality of life score between the two groups(P>0.05).However,after the treatment,the quality of life score of the observation group(72.24±6.08) was significantly higher than that of the control group(68.19±5.66),and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The1-year survival rate and 2-year survival rate of the observation group were significantly higher than those of the control group,and the differences were statistically significant(P<0.05).Conclusions:Docetaxel,Oxaliplatin combined with Tegafur in the treatment of advanced gastric cancer is superior to Oxaliplatin and Tegafur.Moreover,it can effectively improve the quality of life of the patients and prolong their survival time.

关 键 词：多西他赛 奥沙利铂 替吉奥 晚期胃癌 

分 类 号：R735.2[医药卫生—肿瘤]